Literature DB >> 11801436

Do high or low doses of anxiolytics and hypnotics affect mismatch negativity in schizophrenic subjects? An EEG and MEG study.

Kiyoto Kasai1, Haruyasu Yamada, Satoru Kamio, Kazuyuki Nakagome, Akira Iwanami, Masato Fukuda, Masato Yumoto, Kenji Itoh, Ichiro Koshida, Osamu Abe, Nobumasa Kato.   

Abstract

OBJECTIVE: Many studies have demonstrated mismatch negativity (MMN) attenuation in schizophrenia. Recently, investigators have shown that GABAergic inhibitory neurons may regulate MMN generation. Considering that a substantial proportion of schizophrenic patients receive anxiolytics and hypnotics that have affinity to GABA(A) receptors to reduce their comorbid symptoms of anxiety and sleep disturbances, we need to assess whether anxiolytics/hypnotics might affect their MMN generation. The aim of this study is to assess the possibility that high or low doses of anxiolytics/hypnotics received by schizophrenic subjects affect their mismatch negativity (MMN), using event-related potentials (ERPs) and magnetoencephalography (MEG).
METHODS: Twenty-three and 16 patients with schizophrenia participated in the ERP and MEG studies, respectively. Three types of MMN (MMN in response to a duration change of pure-tone stimuli, within-category vowel change (Japanese vowel /a/ with short versus long duration), and across-category vowel change (vowel /a/ versus /o/)) were recorded.
RESULTS: High or low doses of benzodiazepine had no significant effects on MMN amplitude/magnetic MMN power, topography/laterality, or latency under any conditions of the ERP or MEG study.
CONCLUSIONS: These results suggest that chronic administration of anxiolytics/hypnotics does not significantly affect MMN in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11801436     DOI: 10.1016/s1388-2457(01)00710-6

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  18 in total

Review 1.  Inhibitory deficit in schizophrenia is not necessarily a GABAergic deficit.

Authors:  Diogo R Lara
Journal:  Cell Mol Neurobiol       Date:  2002-06       Impact factor: 5.046

Review 2.  Neurophysiological models for new treatment development in schizophrenia: early sensory approaches.

Authors:  Daniel C Javitt
Journal:  Ann N Y Acad Sci       Date:  2015-02-26       Impact factor: 5.691

3.  Frontal Glutamate and γ-Aminobutyric Acid Levels and Their Associations With Mismatch Negativity and Digit Sequencing Task Performance in Schizophrenia.

Authors:  Laura M Rowland; Ann Summerfelt; S Andrea Wijtenburg; Xiaoming Du; Joshua J Chiappelli; Nithin Krishna; Jeffrey West; Florian Muellerklein; Peter Kochunov; L Elliot Hong
Journal:  JAMA Psychiatry       Date:  2016-02       Impact factor: 21.596

4.  Processing of affective speech prosody is impaired in Asperger syndrome.

Authors:  Pirjo Korpilahti; Eira Jansson-Verkasalo; Marja-Leena Mattila; Sanna Kuusikko; Kalervo Suominen; Seppo Rytky; David L Pauls; Irma Moilanen
Journal:  J Autism Dev Disord       Date:  2006-11-04

Review 5.  Auditory dysfunction in schizophrenia: integrating clinical and basic features.

Authors:  Daniel C Javitt; Robert A Sweet
Journal:  Nat Rev Neurosci       Date:  2015-09       Impact factor: 34.870

Review 6.  [Mismatch negativity in schizophrenia research. An indicator of early processing disorders of acoustic information].

Authors:  T Rosburg; I Kreitschmann-Andermahr; H Sauer
Journal:  Nervenarzt       Date:  2004-07       Impact factor: 1.214

Review 7.  Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.

Authors:  Douglas L Boggs; Jon Carlson; Jose Cortes-Briones; John H Krystal; D Cyril D'Souza
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

8.  Nicotine, Auditory Sensory Memory, and sustained Attention in a Human Ketamine Model of Schizophrenia: Moderating Influence of a Hallucinatory Trait.

Authors:  Verner Knott; Dhrasti Shah; Anne Millar; Judy McIntosh; Derek Fisher; Crystal Blais; Vadim Ilivitsky
Journal:  Front Pharmacol       Date:  2012-09-28       Impact factor: 5.810

9.  Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state.

Authors:  Yuko Higuchi; Tomiki Sumiyoshi; Tomonori Seo; Tomohiro Miyanishi; Yasuhiro Kawasaki; Michio Suzuki
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

10.  Neuronal network pharmacodynamics of GABAergic modulation in the human cortex determined using pharmaco-magnetoencephalography.

Authors:  Stephen D Hall; Gareth R Barnes; Paul L Furlong; Stefano Seri; Arjan Hillebrand
Journal:  Hum Brain Mapp       Date:  2010-04       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.